A new study suggests that certain dietary changes may be more effective than medication.

Irritable bowel syndrome is one of the most common and perplexing conditions gastroenterologists treat. It affects an estimated 6 percent of people in the United States, with more women diagnosed than men, and causes symptoms so debilitating they can be hard to ignore, including abdominal pain, bloating, diarrhea and constipation.

Scientists don’t know exactly what causes I.B.S., and there is no cure, so the condition is often difficult to manage.

But a new study, published today in the journal The Lancet Gastroenterology and Hepatology, offers clues for how best to find relief.

The telltale symptoms of I.B.S. are chronic abdominal pain, along with diarrhea, constipation or both, said Dr. Brian Lacy, a gastroenterologist at the Mayo Clinic in Jacksonville, Fla. Bloating is also a common complaint, he said.

Treatments often include managing the symptoms with changes to your diet or taking medications, which can include over-the-counter laxatives and antidiarrheals; certain antidepressants; and other prescription medications, like linaclotide and lubiprostone, both of which can increase fluid in the gut and the movements of your intestines. Yet few studies have examined whether dietary changes or medications are best for relief.

The most robust research available on dietary strategies has found that following a low-FODMAP diet — which involves avoiding foods like wheat-based products, legumes, some nuts, certain sweeteners, most dairy products and many fruits and vegetables — can reduce I.B.S. symptoms in most people, said Dr. William Chey, a gastroenterologist at Michigan Medicine.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.


Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.


Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.